Literature DB >> 18160170

The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats.

Tatsuhiro Ishida1, Syuntaro Kashima, Hiroshi Kiwada.   

Abstract

We earlier reported that PEGylated liposomes lose their long-circulating property when they are administered twice in the same animal within certain intervals. We recently proposed that anti-PEG IgM elicited by the first dose PEGylated liposomes selectively binds to the surface of a second dose, subsequently leading to substantial complement activation and complement-receptor mediated uptake of the second dose by hepatic Kupffer cells. In this study we found, by using a single-pass liver perfusion technique, that the first dose does not increase the intrinsic phagocytic activity of the Kupffer cells. It was also found that only serum obtained from rats that had received a first dose is able to enhance the hepatic uptake of test dose. The conditioned-serum-dependent hepatic uptake was completely abolished by pre-treatment of the serum at 56 degrees C for 30 min, which inhibits the complement activity. Conclusively, our results strongly support our earlier proposal that complement activation caused by anti-PEG IgM elicited by the first dose is a major cause of the initiation of the accelerated blood clearance of a subsequent dose PEGylated liposome in the ABC phenomenon.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160170     DOI: 10.1016/j.jconrel.2007.11.009

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  34 in total

Review 1.  Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.

Authors:  Alyssa B Chinen; Chenxia M Guan; Jennifer R Ferrer; Stacey N Barnaby; Timothy J Merkel; Chad A Mirkin
Journal:  Chem Rev       Date:  2015-08-27       Impact factor: 60.622

Review 2.  Using exosomes, naturally-equipped nanocarriers, for drug delivery.

Authors:  Elena V Batrakova; Myung Soo Kim
Journal:  J Control Release       Date:  2015-08-01       Impact factor: 9.776

3.  Lipid-Mediated Targeting with Membrane-Wrapped Nanoparticles in the Presence of Corona Formation.

Authors:  Fangda Xu; Michael Reiser; Xinwei Yu; Suryaram Gummuluru; Lee Wetzler; Björn M Reinhard
Journal:  ACS Nano       Date:  2016-01-06       Impact factor: 15.881

4.  Exosomes as drug delivery vehicles for Parkinson's disease therapy.

Authors:  Matthew J Haney; Natalia L Klyachko; Yuling Zhao; Richa Gupta; Evgeniya G Plotnikova; Zhijian He; Tejash Patel; Aleksandr Piroyan; Marina Sokolsky; Alexander V Kabanov; Elena V Batrakova
Journal:  J Control Release       Date:  2015-03-31       Impact factor: 9.776

Review 5.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

Review 6.  Exosomes as Therapeutic Vehicles for Cancer.

Authors:  Whasun Lim; Han-Soo Kim
Journal:  Tissue Eng Regen Med       Date:  2019-04-23       Impact factor: 4.169

Review 7.  Engineering of extracellular vesicles as drug delivery vehicles.

Authors:  Sung-Man Kim; Han-Soo Kim
Journal:  Stem Cell Investig       Date:  2017-09-12

8.  Questioning the Use of PEGylation for Drug Delivery.

Authors:  Johan J F Verhoef; Thomas J Anchordoquy
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

Review 9.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 10.  Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.

Authors:  Anna N Ilinskaya; Marina A Dobrovolskaia
Journal:  Toxicol Appl Pharmacol       Date:  2016-01-07       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.